Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

NCT03787680 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Olaparib
DRUG: AZD6738

Sponsor

University of Michigan Rogel Cancer Center